Bineui turns metabolic tests into a self-service offering as breath tests move from labs to gyms

Bineui, a company specializing in metabolic sensing technologies, is preparing to launch its new device, Bineui 2.0, in a move that aims to turn laboratory breath measurements into a fully self-service offering without the need for specialist technicians. The device uses a mask that covers the nose and mouth and is mounted behind the head, allowing the user to sit and breathe continuously for eight minutes after pressing the start button. The system accurately measures oxygen consumption and carbon dioxide exhalation, then translates those gas flows through its software into specific recommendations on training, nutrition and lifestyle.

Metabolic tests that have long been limited to professional athletes and clinical labs are now moving toward a direct-operation model within sports facilities and pharmacies.Historically, respiratory gas analyzers required large, costly carts and trained personnel to operate, limiting their use to hospitals and advanced sports-medicine departments for measuring the maximal oxygen consumption metric known as VO₂ max. The new system tracks twenty-three vital indicators, including resting metabolic rate and metabolic flexibility, which measures the body’s efficiency in switching between fat and carbohydrate burning. These data are not provided with comparable accuracy by conventional blood tests for determining daily calorie needs and appropriate exercise types.

The device was designed in collaboration with Design Group Italy in Milan after intensive development cycles to achieve a compact, low-component architecture that raises operational reliability. To address the post-pandemic challenge of shared use, the costly electronic unit was made completely detachable from the silicone mask and straps, allowing a single facility to share the electronics among hundreds of users while each retains their personal headset. Despite measurement accuracy, the company maintains a cautious regulatory stance; the device is not approved by the U.S. Food and Drug Administration as a medical diagnostic tool, and the company classifies it as a fitness and body-composition device similar to smart scales, meaning a physician cannot prescribe therapeutic drugs based solely on its results at present.

The company uses a B2B subscription model with monthly fees ranging from $400 to over $1,000, covering hardware, software, training and marketing materials. Its client list includes the Equinox club chain, Four Seasons hotels, the Red Bull team, the NBA, and the Mount Sinai health network. Currently, 85 percent of the system’s business is concentrated in the U.S. market, with profitability and annual growth exceeding 100 percent, and a workforce of 110 employees. The company is preparing a Series B financing round within six to twelve months, having raised $22 million to date, including a recent $11 million round involving the 50 Years fund and Lars Rasmussen, a co-founder of Google Maps.

This technological shift reshapes operational priorities in preventive health and sports sectors across the Gulf, Egypt and the Arab Levant markets.The region is seeing a notable expansion of longevity-medicine clinics and upscale health clubs seeking new competitive advantages. Moving the metabolic test from a complex procedure that requires organ-specialist staff and high operating costs to a self-operating device gives local facilities the ability to offer laboratory-grade measurement as a core step when onboarding each new client. Here, commercial value shifts from monopolizing expensive testing equipment to the skill of reading data and building customized nutrition and training plans, while health project managers must remain attentive to the strict regulatory boundaries set by regional health authorities between classifying devices as wellness tools and using them in medical consulting and diagnosis.

The new device sits in a middle ground between smart watches and bands such as Apple, Garmin and Whoop, which estimate oxygen consumption using pulse algorithms, and fully integrated clinical laboratory carts. The company aims in the long term to leverage its growing database to monitor vital markers for chronic diseases and tumors via exhaled compounds, although this clinical ambition remains subject to complex regulatory requirements that may take several years before becoming an approved diagnostic reality.